Syndax Pharmaceuticals Is Down 51% Even Though Sales Rose

Simply Wall St.11-05 16:41

Syndax Pharmaceuticals has had a packed 2026, from strong Q1 and Q2 updates on Revuforj and Niktimvo to an abrupt share-price hit after axatilimab failed its Phase 2 IPF trial. Investors who held ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681078041?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-05 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681078041","market":"sg","top_or_hot":-1,"title":"Syndax Pharmaceuticals Is Down 51% Even Though Sales Rose","media":"Simply Wall St.","content":"<div>\n<p>Syndax Pharmaceuticals has had a packed 2026, from strong Q1 and Q2 updates on Revuforj and Niktimvo to an abrupt share-price hit after axatilimab failed its Phase 2 IPF trial. Investors who held ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-is-down-51-even-though-sales-rose\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syndax Pharmaceuticals Is Down 51% Even Though Sales Rose</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyndax Pharmaceuticals Is Down 51% Even Though Sales Rose\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-05 16:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-is-down-51-even-though-sales-rose><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Syndax Pharmaceuticals has had a packed 2026, from strong Q1 and Q2 updates on Revuforj and Niktimvo to an abrupt share-price hit after axatilimab failed its Phase 2 IPF trial. Investors who held ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-is-down-51-even-though-sales-rose\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDX","symbol_name":"Syndax Pharmaceuticals, Inc. ","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-is-down-51-even-though-sales-rose","article_id":"2681078041","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-is-down-51-even-though-sales-rose","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681078041","pubTimestamp":1793868092,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 5, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"尽管销售额增长，Syndax Pharmaceuticals 仍下跌 51%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1.5},"content_text":"Syndax Pharmaceuticals has had a packed 2026, from strong Q1 and Q2 updates on Revuforj and Niktimvo to an abrupt share-price hit after axatilimab failed its Phase 2 IPF trial. Investors who held Syndax Pharmaceuticals from the start of the year are down 50.9%, including dividends. If you had made that call on 1 January, how should the blend of early optimism and later setbacks change what you now expect from its concentrated oncology portfolio? Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value. The move put Syndax Pharmaceuticals in the middle of this trade. Scan 38 healthcare AI stocks for other companies exposed to it. AdvertisementThe Argument You Would Have Been Weighing Up On Syndax Pharmaceuticals The shares cost US$21.01 at the start of the period, and Syndax Pharmaceuticals sat between two sharply different stories. The bullish narrative put Fair Value at US$36.55, built on revenue growth assumptions of 97.8% and a move from a very large loss margin to 7.2% in three years, driven by broader Revuforj and Niktimvo usage. The bearish view set Fair Value at US$19 and leaned on a profit margin assumption of 16.3% and a 27.9x future P/E. It also stressed the risk that heavy reliance on two drugs and pricing pressure could cap progress. NasdaqGS:SNDX Trailing 12-Month Earnings & Revenue History as at Nov 2026 What The Evidence Did To The Syndax Pharmaceuticals Argument The big swing factor was axatilimab’s failed Phase 2 IPF trial, which directly challenged the bullish case that treated Niktimvo’s label expansions as a core growth driver. Strong Q1 and Q2 updates on Revuforj and Niktimvo, together with Q3 2026 revenue of US$83.3 million and a less negative net margin of 59.3%, supported the more cautious story. Profit remains in loss territory, so the profitability promise is still unproven. The lesson is simple. When you see a forecast built on one or two drugs, test it against later trial outcomes and the net margin trend, not just headline revenue. What You Would Be Paying For In Syndax Pharmaceuticals Today Syndax Pharmaceuticals now trades at US$10.45, and the selected Narrative’s Fair Value sits above that price. The argument focuses on Revuforj and Niktimvo potentially developing into larger oncology franchises while the broader pipeline gradually widens potential earnings power. The question for you is whether the current drop only reflects short term IPF disappointment. A buyer today would need to believe that commercial momentum in Revuforj and Niktimvo holds up while fixed operating costs remain contained. \"The current valuation implies the market is still discounting the scale of Revuforj and Niktimvo cash flows and gives limited credit to the pipeline. This is consistent with a view that Syndax Pharmaceuticals is undervalued.\" One Narrative disagrees with today's price. → See where this Narrative says Syndax Pharmaceuticals should trade Another Way To Read Syndax Syndax Pharmaceuticals leaves you thinking about one thing. Who else is fighting the same oncology and immunology battles from a different angle? Here, one giant drug maker is rebuilding around non pandemic treatments. It is leaning into obesity medicine and cancer drugs that link targeted antibodies with toxic payloads. Those efforts are meant to replace fading cash flows and reshape its earnings mix. The same push puts fresh attention on how efficiently research spending turns into durable therapies. If you are testing Syndax against peers, that shift matters. It hints at how a large rival is trying to balance cost cuts, trial risk and a crowded drug pipeline. It is written up in full, assumptions and all. → Explore the Narrative that puts this company 17% above its price This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681078041","isCrawlerRequest":true}